// Real-Time Intelligence Feed

Financial Intelligence.
Real-Time.

SEC 8-K filings, insider trades, FDA approvals, Federal Reserve statements, and market-moving events — AI-curated, updated every 60 seconds.

13,893
Stories Indexed
Live
Feed Status
6
Data Sources
AllEarningsFDAM&AInsider TradingRegulatoryOfferingLeadershipRestructuringDividendInstitutional HoldingsBankruptcy
FDA · 13,893 results Live
FDA ANNORA Jun 17 — 0.00

FDA Approves Unknown Drug — ANNORA PHARMA

Annora Pharma has received final FDA approval for its Abbreviated New Drug Application (ANDA217329), bringing market implications as the generic alternative readies launch pending …

FDA CREEKWOOD Jun 16 — 0.00

FDA Approves Unknown Drug — CREEKWOOD PHARMS

Creekwood Pharmaceuticals has been granted FDA approval for an Abbreviated New Drug Application (ANDA #218875), a regulatory milestone poised to enhance the company’s market share …

FDA Sun Jun 15 — 0.00

FDA Approves PERAMPANEL — Sun Pharmaceutical Industries, Inc.

1. **Analyze the Request:** * **Topic:** FDA drug approval. * **Details:** * Brand: PERAMPANEL * Generic: PERAMPANEL * Substance: PERAMPA…

FDA Gland Jun 11 — 0.00

FDA Approves BRIMONIDINE TARTRATE AND TIMOLOL MALEATE OPHTHALMIC SOLUTION — Gland Pharma Limited

Gland Pharma Limited received FDA approval for its ophthalmic solution containing Brimonidine Tartrate and Timolol Maleate, marking a strategic expansion of its generic portfolio. …

FDA Aurobindo Jun 9 — 0.00

FDA Approves CEPHALEXIN — Aurobindo Pharma Limited

# FDA Approves Aurobindo Pharma's Cephalexin Oral Formulation The U.S. Food and Drug Administration has approved Aurobindo Pharma Limited's abbreviated new drug application (ANDA2…

FDA RADIOMEDIX Jun 8 — 0.00

FDA Approves Unknown Drug — RADIOMEDIX

# FDA Approves Radiopharmaceutical Generic from Radiomedix The FDA approved Radiomedix's generic radiopharmaceutical application (ANDA216410) on June 8, 2026, positioning the comp…

FDA Amneal Jun 8 — 0.00

FDA Approves MACITENTAN — Amneal Pharmaceuticals NY LLC

Amneal Pharmaceuticals NY LLC secured FDA approval for oral MACITENTAN on June 8, 2026, a strategic move expected to diversify the company’s portfolio and intensify competition wit…

FDA HIBROW Jun 4 — 0.00

FDA Approves Unknown Drug — HIBROW HLTHCARE

HIBROW HLTHCARE announced FDA approval for ANDA 215485, a strategic regulatory milestone that advances the company's generic pipeline toward a 2026 delivery. Market analysts are li…

FDA Somerset Jun 3 — 0.00

FDA Approves TOFACITINIB — Somerset Therapeutics, LLC

# FDA Approves Generic Tofacitinib; Somerset Therapeutics Enters Competitive JAK Inhibitor Market Somerset Therapeutics, LLC has received FDA approval for its generic tofacitinib …

FDA Novadoz Jun 3 — 0.00

FDA Approves TOFACITINIB — Novadoz Pharmaceuticals LLC

# FDA Approves Generic Tofacitinib from Novadoz Pharmaceuticals Novadoz Pharmaceuticals LLC has received FDA approval for its generic tofacitinib citrate oral formulation, marking…

FDA Sun Jun 3 — 0.00

FDA Approves TOFACITINIB — Sun Pharmaceutical Industries, Inc.

Sun Pharmaceutical Industries has received FDA approval for its generic tofacitinib citrate oral formulation, a regulatory milestone expected to drive revenue growth as the company…

FDA Breckenridge Jun 3 — 0.00

FDA Approves TOFACITINIB — Breckenridge Pharmaceutical, Inc.

Breckenridge Pharmaceutical’s FDA approval for oral tofacitinib citrate is set to introduce aggressive competition to the branded market, likely pressuring the sole brand-name entr…

FDA Aurobindo Jun 3 — 0.00

FDA Approves TOFACITINIB — Aurobindo Pharma Limited

Aurobindo Pharma received FDA approval for its generic tofacitinib citrate oral tablets on June 3, 2026, establishing a new entrant in the JAK inhibitor market. This authorization …

FDA Novadoz Jun 3 — 0.00

FDA Approves TOFACITINIB — Novadoz Pharmaceuticals LLC

Novadoz Pharmaceuticals secured FDA approval June 3, 2026, for oral Tofacitinib Citrate tablets, positioning the firm to capitalize on a significant rheumatoid arthritis market. Th…

FDA Amneal Jun 2 — 0.00

FDA Approves ROMIDEPSIN — Amneal Pharmaceuticals LLC

# FDA Approves Generic Romidepsin from Amneal Pharmaceuticals Amneal Pharmaceuticals LLC has received FDA approval for generic romidepsin intravenous formulation, expanding the co…

FDA Zydus Jun 1 — 0.00

FDA Approves FLUORESCEIN — Zydus Pharmaceuticals USA Inc.

# FDA Approves Zydus Pharmaceuticals' Generic Fluorescein Sodium Injection Zydus Pharmaceuticals USA Inc. received FDA approval for its generic fluorescein sodium intravenous inje…

FDA CONCORD Jun 1 — 0.00

FDA Approves Unknown Drug — CONCORD BIOTECH LTD

Concord Biotech Ltd’s FDA approval of ANDA218566 is expected to enhance the company’s long-term market position and revenue potential, paving the way for strategic commercial activ…

FDA HIKMA May 29 — 0.00

FDA Approves Unknown Drug — HIKMA

# FDA Approves Hikma's Generic Drug Application Hikma Pharmaceuticals received FDA approval for ANDA 220562 on May 29, 2026, expanding its generic drug portfolio and positioning t…

FDA Novadoz May 29 — 0.00

FDA Approves OXCARBAZEPINE — Novadoz Pharmaceuticals LLC

Novadoz Pharmaceuticals announced the FDA approval of its oral oxcarbazepine tablets (ANDA 209020), a generic version of the anticonvulsant, which is expected to bolster the compan…

FDA Shionogi May 29 — 0.00

FDA Approves XOCOVA — Shionogi Inc.

Shionogi Inc. announced FDA approval for the oral antiviral XOCOVA (ensitrelvir) effective May 29, positioning the company to expand its commercial footprint with a non-injectable …